Gangliosides are sialic acid-containing glycolipids that are mainly localized in the outer leaflet of the plasma membrane of vertebrate cells and are involved in diverse physiological functions such as cell growth, differentiation, and cell-cell recognition(Hakomori, 1990). In the nervous system, gangliosides are highly expressed in neurons and are implicated in neurite outgrowth, synaptogenesis, and modulation of synaptic transmission(Posse de Chaves and Sipione, 2010). In this context, gangliosides have been proposed to act as co-receptors for growth factors (e.g. fibroblast growth factor) and neurotransmitters (e.g. serotonin)(Posse de Chaves and Sipione, 2010). Gangliosides are also localized in some glial cells in both gray and white matter, thereby affecting myelin sheath stability through association with myelin-associated glycoprotein(Schnaar, 2010).
There is immense large body of knowledge on the biosynthesis and catabolism of gangliosides. In brief, gangliosides are synthesized by sequential addition of single sugars catalyzed by multiple glycosyltransferases (Fig. 1). The profiles of ganglioside components in neurons and glia are developmently regulated(Yamamoto et al., 1996; Yu et al., 2009). For instance, the dominant pathway in neurons during the neonate stage is pathway “a”, which starts from GM3 and leads to GT1a via GM1 and GD1a. In adult human brain, four gangliosides (GM1, GD1a, GD1b and GT1b) are mainly produced, and these make up the majority (> 66 %) of gangliosides in the brain(Ando et al., 1978). It is also believed that each ganglioside has a specific function in the brain and is not merely an intermediate metabolite in the synthesis of more prevalent gangliosides(Yamamoto et al., 1996; Yu et al., 2009).
Gangliosides are in turn degraded by various lysosomal hydrolases with the aid of sphingolipid activator proteins. If a specific hydrolase required for this process is partially or totally missing due to a genetic deficit, gangliosides accumulate in the lysosomes and result in lysosomal dysfunction, which manifests as a lysosomal storage diseases (LSD)(Jalanko and Braulke, 2009; Vitner et al., 2010). Furthermore, it has been shown that gangliosides are secondarily upregulated in many other sphingolipidoses(Vitner et al., 2010). In this review, we do not describe the details of LSDs, but we refer to the linkage of LSDs and neurodegenerative diseases in a later section.
Synthesis is depicted starting with lactosylceramide (LacCer). GalNAc-T, GA2/GM2/GD2/GT2 synthase; GalT-II, GA1/GM1/GD1b/GT1c synthase; ST-IV, GM1b/GD1a/GT1b/GQ1c synthase; ST-V, GD1c/GT1a/GQ1b/GP1c synthase; ST-Vα, GD1a/GT1aα/GQ1bα/GP1cα synthase.
Beyond LSDs, gangliosides have been implicated in various pathologies. In particular, evidence has accumulated to suggest a role of gangliosides in age-associated neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). To date, the effect of gangliosides on the pathogenesis of AD is a controversial issue. Many studies suggest that gangliosides stimulate fibrillogenesis of amyloid β-protein (Aβ) in the early stage of pathogenesis(Yanagisawa et al., 1995), whereas others have shown that GM1 ganglioside has a beneficial effect on early onset AD, presumably through the sequestration of Aβ(Matsuoka et al., 2003; Svennerholm, 1994). A limited number of reports also suggest that gangliosides are protective against the pathogenesis of PD(Hadjiconstantinou et al., 1986; Wei et al., 2009b). With this background, the main objective of this review is to outline what is known about the roles of gangliosides in neurodegenerative diseases, including AD and PD. We also examine the linkage of these neurodegenerative diseases to LSDs.
2. Gangliosides stimulate amyloidogenesis in AD
2.1. Aggregation of A in AD
AD is a progressive degenerative disease of the brain with loss of memory and cognition, and is characterized by the two neuropathological hallmarks of senile plaques and neurofibrillary tangles. The former are mainly composed of aggregated Aβ derived from amyloid precursor protein (APP), while the latter consist of paired helical filaments containing hyperphosphorylated tau(Yankner, 2000).
It is well characterized that amyloidogenic Aβ is generated by the consecutive cleavage of two proteases: β- and γ-secretase(Selkoe, 2008). Consistent with biochemical studies demonstrating that Aβ42 is more amyloidogenic compared to Aβ40 and other Aβ forms, it has been shown genetically that increased Aβ42 production is associated with inherited familial AD. In contrast, alternative cleavage of Aβ at amino acid 17 by α-secretase releases sAPPα and excludes production of Aβ. The predominant cleavage product is sAPPα, serving to prevent production of Aβ.
The mechanism of neurotoxicity caused by Aβ is incompletely understood. However, it is generally believed that aggregation of Aβ results in formation of neurotoxic protofibrils and deposition of amyloid plaques(Yankner, 2000). Thus, factors regulating Aβ aggregation and secretion are very important for the etiology of AD.
2.2. Ganglioside interactions with A
Considerable attention has been focused on the roles of gangliosides in the development of AD, since a number of
It is of particular interest that several Aβ mutations in familial AD and hereditary cerebral amyloid angiopathy show distinct ganglioside affinity (Fig. 3A). Aβ with the Arctic-type mutation (E22G) rapidly assembles in the presence of GM1, similarly to wild type Aβ(Yamamoto et al., 2007). In contrast, Aβ with the Dutch-type mutation (E22Q) assembles in the presence GM2 or GM3(Yamamoto et al., 2005a), and Aβ with the Flemish-type mutation (A21G) assembles in the presence GD3(Yamamoto et al., 2005a). The pathological meaning of these phenomena is unknown.
2.3. Regulatory roles of gangliosides on APP processing
Besides a direct interaction with Aβ, gangliosides might also dysregulate APP processing associated with increased secretion of Aβ, which could ultimately lead to enhanced aggregation of Aβ (Fig. 2B). In support of this view, exogenous addition of GM1 in cultured neurons enhances Aβ production in parallel with inhibition of sAPPα secretion(Zha et al., 2004). These results suggest that GM1 regulates processing of APP by regulating the activity of secretases. There are two potential mechanisms for the inhibition of α-secretase cleavage by GM1(Zha et al., 2004). First, stiffening of the membrane due to GM1 loading may decrease sAPPα by inhibiting lateral movement and preventing the required contact between the enzyme and substrate. Second, since GM1 has been reported to have an inhibitory action on PKC, and sAPPα is positively regulated by PKC activation, GM1 may inhibit sAPPα secretion by inhibiting PKC activity. Both hypotheses require examination in further experimental work.
It is also possible that GM1 could increase β- and/or γ-secretase activity directly or indirectly. Indeed, since these secretases are thought to be localized to rafts, there might be as yet unknown biological functions underlying the connection between gangliosides and the secretases. Such a view may fit with a recent suggestion that amyloidogenic processing of APP depends on lipid rafts(Vetrivel and Thinakaran, 2010). Rafts are lateral assemblies of sphingolipids and cholesterol within the membrane. In this context, both gangliosides and cholesterol have been shown to bind to Aβ and facilitate amyloid fibril formation(Kakio, 2001). Taken together, these results suggest that processing of APP and generation of Aβ can be modulated depending on the cellular content of gangliosides.
2.4. Gangliosides and tau
Currently, only a few reports have suggested a role of gangliosides in tau aggregation and NFT formation. McGeer and co-workers showed that the monoclonal antibody A2B5, which recognizes neuronal surface gangliosides, was strongly immunopositive for many NFTs, neuropil threads, and dystrophic neurites in AD(Tooyama et al., 1992). Similar strong immunoreactivities were observed in globose-type NFTs in cases of progressive supranuclear palsy cases and in Pick bodies in Pick's disease(Yasuhara et al., 1995). Takahashi et al. showed that fetal antigens such as the C-series gangliosides and microtubule-associated protein 5 immunostained dystrophic neurites of senile plaques, NFTs and neuropil threads in the cerebral cortex in AD brain, with similar immunostaining patterns to those of tau(Takahashi et al., 1991). These results suggest that regeneration or sprouting of neurons is ongoing in association with the re-induction of gene expression characteristics in the AD brain in the early stage of development. Further studies are required to investigate the interesting possibility that gangliosides bind with tau, and that this leads to formation of NFTs and other histopathologies in AD.
2.5. Glial activation by gangliosides
It has been well characterized that gangliosides are involved in regulation of glial activation(Cammer and Zhang, 1996). In this context, recent clinical reports show that reactive astrocytes have ganglioside GD3, unlike protoplasmic astrocytes, in patients with Creutzfeldt-Jakob disease and cerebral infarction(Kawai et al., 1999). Thus, it is likely that expression and localization of individual ganglioside subtypes in neurons and glia might change under the neurodegenerative conditions of AD and PD.
3. Amelioration of the neuropathology of AD by gangliosides
As described above, many studies have shown a role for gangliosides as stimulators of Aβ amyloidogenesis in the early stage of AD. However, some studies have focused on the beneficial effects of gangliosides in treatment of AD. Svennerholm and Gottfries showed that the ganglioside content is reduced in early-onset or familial AD to 58-70% of that of control brains in gray matter and to 81% in frontal white matter(Svennerholm and Gottfries, 1994). Notably, both GT1b and GQ1b were significantly decreased, while GD3 was increased, suggesting that metabolism of gangliosides may be dysregulated in AD. Furthermore, given the neurotrophic activities of gangliosides(Fusco et al., 1993), it seems likely that loss of gangliosides is correlated with the severity of AD. Based on this idea, Svennerholm performed intraventricular infusion of GM1 for AD brains and concluded that GM1 treatment was effective for early onset AD, presumably through sequestration of Aβ by GM1(Svennerholm, 1994). More recently, Matsuoka et al. found that PS/APP mice administered peripherally with gelsolin or GM1 showed a substantial decrease in aggregated Aβ40 and Aβ42 in the brain. The result is reminiscent of the “sink effect” leading to reduction of Aβ accumulation in the brain following passive immunization with anti-Aβ antibodies (De Mattos et al., 2002). Based on this result, a novel therapeutic strategy was proposed using derivatives that are structurally related to gangliosides for specific targeting of pathogenic peptides in the periphery.
4. Roles of gangliosides in the pathogenesis of PD and related disorders
PD is a progressive degenerative disorder of dopaminergic neurons in the substantia nigra. PD manifests clinically as movement disorder, including tremor, rigidity, and gait disturbance, while non-motor type symptoms such as cognitive difficulties and sleep problems may arise in advanced stages(Hashimoto and Masliah, 1999; Trojanowski et al., 1998). Because the pathology of PD is characterized by accumulation of α-synuclein into inclusions called Lewy bodies in neurons, the disease is classified as a synucleinopathy. This spectrum of diseases also includes dementia with Lewy bodies (DLB), multiple system atrophy, and neurodegeneration with brain iron accumulation type I(Hashimoto and Masliah, 1999; Trojanowski et al., 1998).
α-Synuclein is a presynaptic protein of unknown function that is characterized by a natively unfolded structures, with highly conserved N-termini and divergent C-terminal acidic regions in the synuclein family of peptides, which has two other members: β- and γ- synuclein(Hashimoto and Masliah, 1999). Importantly, α-synuclein is distinct from other members of the synuclein family in that it possesses a highly hydrophobic central region that has been identified as a non-amyloid β component in Alzheimer disease(Ueda et al., 1993). Since the discovery of the linkage of two missense mutations (A53T and A30P) to familial PD(Kruger et al., 1998; Polymeropoulos et al., 1997), numerous histopathological studies have shown that α-synuclein fibrils are the major constituent in Lewy bodies and glial cell inclusions in synucleinopathies(Hashimoto and Masliah, 1999). Furthermore, another missense mutation, E46K, was recently identified for DLB(Zarranz et al., 2004). All the mutant proteins have a greater propensity for self-association and aggregation compared with wild-type α-synuclein, suggesting that aggregation and protofibril formation of α-synuclein has a causative role in stimulation of neurodegenerative disorders.
4.2. Gangliosides bind with -synuclein
Among various modulators, gangliosides may be particularly important as endogenous molecules that negatively regulate α-synuclein aggregation. In this regard, Fink and colleagues investigated the interactions between various brain sphingolipids and α-synuclein and found that α-synuclein specifically bound to ganglioside GM1(Martinez et al., 2007). Furthermore, GM1 strongly inhibited α-synuclein fibrillation, whereas total brain gangliosides, GM2, GM3, and asialo-GM1 had weak inhibitory effects on α-synuclein fibrillation and induced some α-helical structure(Martinez et al., 2007). Given the immunoreactivity of α-synuclein in rafts, it is possible that α-synuclein is recruited by GM1 to lipid raft regions in presynaptic membranes. In this context, perturbation of GM1/raft association could induce changes in α-synuclein that contribute to the pathogenesis of PD. It is also noteworthy that GM3 may have a protective effect against channelopathy caused by α-synuclein(Lashuel et al., 2002). The ability of α-synuclein oligomers to form ionic channels was postulated as a channelopathy mechanism in human brain. Di Pasquale et al. identified a ganglioside-binding domain in the N-terminal region of α-synuclein (aa 34-50) and showed that altered ion channel formation by the DLB-linked E46K mutant of α-synuclein was corrected by GM3, but not by GM1 ganglioside(Di Pasquale et al., 2010). This result suggests that GM3, a minor brain ganglioside that is increasingly expressed with aging, might play a critical role in the neurotoxicity of α-synuclein. It is also an intriguing possibility that gangliosides might have affinity for α-synuclein mutations, as is the case for Aβ mutations (Fig. 3B).
4.3. Protective effects of gangliosides on lysosomal pathology of synucleinopathies
Results in cell-free systems indicate that gangliosides may protect against synucleinopathies, and we have shown that changes in endogenous ganglioside levels affect lysosomal pathology in a cellular model of synucleinopathy(Wei et al., 2009a; Wei et al., 2007). In this work, DLB-linked P123H β-synuclein neuroblastoma cells transfected with α-synuclein were used as a model system because these cells have extensive formation of lysosomal inclusion bodies. Treatment of the cells with D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glycosyl ceramide synthase, resulted in various features of lysosomal pathology, including compromised lysosomal activity, enhanced lysosomal membrane permeabilization, and increased cytotoxicity (Fig. 4). Consistent with these findings, expression levels of lysosomal membrane proteins, ATP13A2 and LAMP-2, were significantly decreased, and electron microscopy demonstrated alterations in the lysosomal membrane structures. Furthermore, accumulation of P123H β-synuclein and α-synuclein was significant in PDMP-treated cells because of the suppressive effect of PDMP on the autophagy pathway. Finally, the detrimental effects of PDMP on the lysosomal pathology were significantly ameliorated by addition of gangliosides to the cultured cells. These data suggest that endogenous gangliosides have protective roles against lysosomal pathology of synucleinopathies.
4.4. Protective effects of gangliosides in an MPTP model
There are few reports on the roles of gangliosides in synucleinopathies
Despite the protective effects of gangliosides on drug-induced Parkinsonism, clinical trials of gangliosides for treatment of PD have been suspended because of the occasional development of an acute motor neuropathy (e.g. Guillain-Barré syndrome). Therefore, new derivatives of gangliosides are required that might efficiently sequester α-synuclein without causing neuropathy and other side effects.
5. Common pathology between neurodegenerative diseases and LSDs
5.1. LSDs are associated with Lewy bodies and NFTs
In the previous sections, we have described how gangliosides might be involved in the pathogenesis of neurodegenerative disorders such as AD and PD. Conversely, accumulating evidence suggests that LSDs, including Gaucher disease, Sandhoff disease, Nieman-Pick C1 disease, Tay-Sachs disease, metachromatic leukodystrophy, -galactosialidosis, and adrenoleukodystrophy, are associated with neuropathologies such as Lewy bodies and NFT(Saito et al., 2004; Suzuki et al., 2003; Suzuki et al., 2007). Furthermore, a recent study suggested that LSDs and neurodegenerative diseases are characterized by disorder of the autophagy-lysosomal pathway(Settembre et al., 2008; Tamboli et al., 2011). The overlapping pathology between the two disease spectrums might be attributable to direct and/or indirect interactions of gangliosides with amyloidogenic proteins, including Aβ and α-synuclein. However, the two disease types are currently treated as completely separate entities, which may mainly be due to the differences in onset age and clinical symptoms.
5.2. Genetic link between neurodegenerative diseases and LSDs
Emerging genetic evidence suggests that the distinction between the two disease types should be reconsidered. In this regard, several cohort studies of screening for the glucocerebrosidase gene in patients with PD and DLB have identified a high frequency of mutations(Hruska et al., 2006; Mitsui et al., 2009; Sidransky, 2004), suggesting that mutation of this gene is a risk factor for α-synucleinopathies. Furthermore, the affinity of gangliosides for amyloidogenic proteins raises the intriguing possibility that the two disease spectrums are linked to each other more closely than previously thought. GM1 associates with the -sheet structure of α-synuclein (probably with the central NAC region), while GM3 preferentially binds to the N-terminus of α-synuclein. GM2 is abundantly accumulated in Sandhoff disease and Tay-Sachs disease, both of which have a Lewy body pathology(Suzuki et al., 2003), and this raises the question of how GM2 interacts with α-synuclein. Furthermore, other sphingolipids may have affinity for α-synuclein, given the accumulation of α-synuclein in other types of LSDs.
In summary, gangliosides may be involved in the pathogenesis of AD, either by stimulating the seeding step of amyloidogenesis or through deregulation of the processing of APP. On the other hand, addition of gangliosides may be a useful strategy to sequester Aβ, leading to suppression of extracellular deposits of Aβ. In a similar context, the sequestering effects of gangliosides on α-synuclein may protect against an α-synuclein pathology, such as channelopathy and intracellular lysosomal inclusion. Thus, currently available data suggest that gangliosides may act as a double-edged sword in neurodegenerative diseases such as AD and PD.
However, information is still limited and further studies are required to elucidate the roles of gangliosides with respect to Aβ and α-synuclein, and also with tau and glial activation. Finally, the affinity of gangliosides to amyloidogenic proteins is an issue that may provide a key to solve as yet unknown mechanisms underlying common aspects of age-associated neurodegenerative diseases and LSDs.
This work was supported in part by a grant-in-aid for Science Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors have no conflict of interest to declare.
Ando S. Chang N. C. Yu R. K. 1978High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. , 89 2 437 450 0003-2697
Ariga T. Mc Donald M. P. Yu R. K. 2008Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease--a review. , 49 6 1157 1175 0022-2275
Cammer W. Zhang H. 1996Ganglioside GD3 in radial glia and astrocytes in situ in brains of young and adult mice. , 46 1 18 23 0360-4012
Choo-Smith L. P. Garzon-Rodriguez W. Glabe C. G. Surewicz W. K. 1997Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. , 272 37 22987 22990 0021-9258
De Mattos R. B. Bales K. R. Cummins D. J. Paul S. M. Holtzman D. M. 2002Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. , 295 5563 2264 2267 0036-8075
Di Pasquale E. Fantini J. Chahinian H. Maresca M. Taieb N. Yahi N. 2010Altered ion channel formation by the Parkinson’s-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. , 397 1 202 218 0022-2836
Fusco M. Vantini G. Schiavo N. Zanotti A. Zanoni R. Facci L. Skaper S. D. 1993Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives. , 695 314 317 0077-8923
Hadjiconstantinou M. Rossetti Z. L. Paxton R. C. Neff N. H. 1986Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. , 25 9 1075 1077 0028-3908
Hakomori S. 1990Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. , 265 31 18713 18716 0021-9258
Hashimoto M. Masliah E. 1999Alpha-synuclein in Lewy body disease and Alzheimer’s disease. , 9 4 707 720 1015-6305
Hayashi H. Kimura N. Yamaguchi H. Hasegawa K. Yokoseki T. Shibata M. Yamamoto N. Michikawa M. Yoshikawa Y. Terao K. et al. 2004A seed for Alzheimer amyloid in the brain. , 24 20 4894 4902 0270-6474
Hruska K. S. Goker-Alpan O. Sidransky E. 2006Gaucher disease and the synucleinopathies. , 2006 3 78549 1110-7243
Jalanko A. Braulke T. 2009Neuronal ceroid lipofuscinoses. , 1793 4 697 709 0006-3002
Jonsson G. Gorio A. Hallman H. Janigro D. Kojima H. Luthman J. Zanoni R. 1984Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins. , 12 2-3 459 475 0360-4012
Kakio A. 2001Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid beta-Protein, an Endogenous Seed for Alzheimer Amyloid. , 276 27 24985 24990 0108-3351X
Kawai K. Watarai S. Takahashi H. Ishizu H. Fukai K. Tanabe Y. Yokota O. Kuroda S. 1999Demonstration of ganglioside GD3 in human reactive astrocytes. , 53 1 79 82 1323-1316
Kruger R. Kuhn W. Muller T. Woitalla D. Graeber M. Kosel S. Przuntek H. Epplen J. T. Schols L. Riess O. 1998Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. , 18 2 106 108 1061-4036
Lashuel H. A. Hartley D. Petre B. M. Walz T. Lansbury P. T. Jr 2002Neurodegenerative disease: amyloid pores from pathogenic mutations. , 418 6895 291 0028-0836
Martinez Z. Zhu M. Han S. Fink A. L. 2007GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. , 46 7 1868 1877 0006-2960
Matsuoka Y. Saito M. La Francois J. Gaynor K. Olm V. Wang L. Casey E. Lu Y. Shiratori C. Lemere C. Duff K. 2003Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. , 23 1 29 33 0270-6474
Matsuzaki K. Horikiri C. 1999Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. , 38 13 4137 4142 0006-2960
Mc Laurin J. Chakrabartty A. 1996Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. , 271 43 26482 26489 0021-9258
Mitsui J. Mizuta I. Toyoda A. Ashida R. Takahashi Y. Goto J. Fukuda Y. Date H. Iwata A. Yamamoto M. et al. 2009Mutations for Gaucher disease confer high susceptibility to Parkinson disease. , 66 5 571 576 0003-9942
Polymeropoulos M. H. Lavedan C. Leroy E. Ide S. E. Dehejia A. Dutra A. Pike B. Root H. Rubenstein J. Boyer R. et al. 1997Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. , 276 5321 2045 2047 0036-8075
Posse de Chaves. E. Sipione S. 2010Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. , 584 9 1748 1759 0014-5793
Saito Y. Suzuki K. Hulette C. M. Murayama S. 2004Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. , 63 4 323 328 0022-3069
Schnaar R. L. 2010Brain gangliosides in axon-myelin stability and axon regeneration. , 584 9 1741 1747 0014-5793
Selkoe D. J. 2008Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer’s disease. , 89 245 260 0072-9752
Settembre C. Fraldi A. Jahreiss L. Spampanato C. Venturi C. Medina D. de Pablo R. Tacchetti C. Rubinsztein D. C. Ballabio A. 2008A block of autophagy in lysosomal storage disorders. , 17 1 119 129 0964-6906
Sidransky E. 2004Gaucher disease: complexity in a "simple" disorder. , 83 1-2 6 15 1096-7192
Suzuki K. Iseki E. Katsuse O. Yamaguchi A. Katsuyama K. Aoki I. Yamanaka S. Kosaka K. 2003Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model. , 14 4 551 554 0959-4965
Suzuki K. Iseki E. Togo T. Yamaguchi A. Katsuse O. Katsuyama K. Kanzaki S. Shiozaki K. Kawanishi C. Yamashita S. et al. 2007Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. , 114 5 481 489 0001-6322
Svennerholm L. 1994Gangliosides--a new therapeutic agent against stroke and Alzheimer’s disease. , 55 25-26 2125 2134 0024-3205
Svennerholm L. Gottfries C. G. 1994Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). , 62 3 1039 1047 0022-3042
Takahashi H. Hirokawa K. Ando S. Obata K. 1991Immunohistological study on brains of Alzheimer’s disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5. , 81 6 626 631 0001-6322
Tamboli I. Y. Hampel H. Tien N. T. Tolksdorf K. Breiden B. Mathews P. M. Saftig P. Sandhoff K. Walter J. 2011Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. , 31 5 1837 1849 0270-6474
Tooyama I. Yamada T. Kim S. U. Mc Geer P. L. 1992Immunohistochemical study of A2B5-positive ganglioside in postmortem human brain tissue of Alzheimer disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and control cases. , 136 1 91 94 0304-3940
Trojanowski J. Q. Goedert M. Iwatsubo T. Lee V. M. 1998Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. , 5 10 832 837 1350-9047
Ueda K. Fukushima H. Masliah E. Xia Y. Iwai A. Yoshimoto M. Otero D. A. Kondo J. Ihara Y. Saitoh T. 1993Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 90 23 11282 11286 0027-8424
Vetrivel K. S. Thinakaran G. 2010Membrane rafts in Alzheimer’s disease beta-amyloid production. , 1801 8 860 867 0006-3002
Vitner E. B. Platt F. M. Futerman A. H. 2010Common and uncommon pathogenic cascades in lysosomal storage diseases. , 285 27 20423 20427 0021-9258
Wei J. Fujita M. Nakai M. Waragai M. Sekigawa A. Sugama S. Takenouchi T. Masliah E. Hashimoto M. 2009aProtective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. , 174 5 1891 1909 0002-9440
Wei J. Fujita M. Nakai M. Waragai M. Watabe K. Akatsu H. Rockenstein E. Masliah E. Hashimoto M. 2007Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. , 282 39 28904 28914 0021-9258
Wei J. Fujita M. Sekigawa A. Sekiyama K. Waragai M. Hashimoto M. 2009bGangliosides’ protection against lysosomal pathology of synucleinopathies. , 5 6 860 861 1554-8627
Yamamoto A. Haraguchi M. Yamashiro S. Fukumoto S. Furukawa K. Takamiya K. Atsuta M. Shiku H. 1996Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development. , 66 1 26 34 0022-3042
Yamamoto N. Hirabayashi Y. Amari M. Yamaguchi H. Romanov G. Van Nostrand W. E. Yanagisawa K. 2005aAssembly of hereditary amyloid beta-protein variants in the presence of favorable gangliosides. , 579 10 2185 2190 0014-5793
Yamamoto N. Matsubara E. Maeda S. Minagawa H. Takashima A. Maruyama W. Michikawa M. Yanagisawa K. 2007A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. , 282 4 2646 2655 0021-9258
Yamamoto N. Yokoseki T. Shibata M. Yamaguchi H. Yanagisawa K. 2005bSuppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. , 335 1 45 47 0000-6291X
Yanagisawa K. Odaka A. Suzuki N. Ihara Y. 1995GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. , 1 10 1062 1066 1078-8956
Yankner B. A. 2000The pathogenesis of Alzheimer’s disease. Is amyloid beta-protein the beginning or the end? , 924 26 28 0077-8923
Yasuhara O. Matsuo A. Tooyama I. Kimura H. Mc Geer E. G. Mc Geer P. L. 1995Pick’s disease immunohistochemistry: new alterations and Alzheimer’s disease comparisons. , 89 4 322 330 0001-6322
Yu R. K. Nakatani Y. Yanagisawa M. 2009The role of glycosphingolipid metabolism in the developing brain. , 50Suppl, S440 S445 0022-2275
Zarranz J. J. Alegre J. Gomez-Esteban J. C. Lezcano E. Ros R. Ampuero I. Vidal L. Hoenicka J. Rodriguez O. Atares B. et al. 2004The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. , 55 2 164 173 0364-5134
Zha Q. Ruan Y. Hartmann T. Beyreuther K. Zhang D. 2004GM1 ganglioside regulates the proteolysis of amyloid precursor protein. , 9 10 946 952 1359-4184